reports Archives - AudioMedica.com

Tagged: reports

0
- in News · Oncology
- — 26 Feb, 2008
Chronic Lymphocytic Leukemia After Fludarabine Failure

John Gribben
Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
JOHN GRIBBEN, Bartholemews Hospital, London
New promise for treating chronic lymphocytic leukemia is arising from combining antibody therapies rituximab and alemtuzumab with new drugs such as
…
Read more
Ibritumomab Provides Benefit in Patients with Follicular Lymphoma" /> 0
- in Oncology
- — 11 Dec, 2007
Live Report from ASH:
Ibritumomab Provides Benefit in Patients with Follicular Lymphoma

Anton Hagenbeek
ANTON HAGENBEEK, University Medical Centre Utrecht
For patients with advanced-stage follicular non-Hodgkinâ€™s lymphoma, ibritumomab tiuxetan seems to prolong progression free survival by two years with favourable toxicity. Sarah Maxwell spoke to study author Anton Hagenbeek at the ASH
…
Read more
Can Intensive Immunochemotherapy Cure Mantle Cell Lymphoma?" /> 0
- in Oncology
- — 11 Dec, 2007
Live Report from ASH:
Can Intensive Immunochemotherapy Cure Mantle Cell Lymphoma?

Christian Geisler
CHRISTIAN GEISLER, Rigshospitalet, Copenhagen
Mantle cell lymphoma, which was previously considered incurable, has apparently been cured in some patients on a phase II study. Derek Thorne got the details on the study â€“ which featured an intensive immunochemotherapy
…
Read more
Oblimersen Extends Survival in Chronic Lymphocytic Leukemia" /> 0
- in Oncology
- — 10 Dec, 2007
Live Report from ASH:
Oblimersen Extends Survival in Chronic Lymphocytic Leukemia

Susan Oâ€™Brien
SUSAN O’BRIEN, MD Anderson Cancer Center, Houston
For patients with relapsed or refractory CLL, oblimersen extends survival when added to standard fludarabine/cyclophosphamide chemotherapy. Susan Oâ€™Brien presented data from this phase III trial to the American Society of Hematology
…
Read more
Dasatinib Effective At Two Yearsâ€™ Follow Up in Chronic Phase CML" /> 0
- in Oncology
- — 10 Dec, 2007
Live Report from ASH:
Dasatinib Effective At Two Yearsâ€™ Follow Up in Chronic Phase CML

Richard Stone
RICHARD STONE, Dana-Farber Cancer Institute, Boston
GEORGE CANELLOS, Dana-Farber Cancer Institute
New data shows that dasatinib is giving durable responses in patients with chronic phase chronic myeloid leukemia who have failed, or who cannot tolerate imatinib. So where
…
Read more
0
- in Oncology
- — 10 Dec, 2007
Live Report from ASH: Azacitidine â€˜New Standardâ€™ In High Risk Myelodysplastic Syndromes

Pierre Fenaux
PIERRE FENAUX, Paris 13 University
Results from a phase III study presented at ASH suggest that the hypomethylating agent azacitidine should be the new standard of care for patients with high-risk MDS. Pierre Fenaux of Paris 13 University
…
Read more
Interleukin-2 For Acute Myeloid Leukemia In First Remission?" /> 0
- in Oncology
- — 10 Dec, 2007
Live Report from ASH:
Interleukin-2 For Acute Myeloid Leukemia In First Remission?

Jonathan Kolitz
JONATHAN KOLITZ, Monter Cancer Center, Lake Success, NY
GEORGE CANELLOS, Dana-Farber Cancer Institute
For patients with acute myeloid leukemia in first remission, new data suggests that there may be a benefit from interleukin-2. Derek Thorne got the interim
…
Read more
0
- in Cardiovascular
- — 5 Nov, 2007
TRITON-TIMI 38 Prasugrel Or Clopidogrel In Percutaneous Intevention?

Gordon Tomaselli

Daniel Jones
REFERENCE: Late Breaking Clinical Trials 1, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
GORDON TOMASELLI, Johns Hopkins University, Baltimore
COMMENT: DANIEL JONES, President, American Heart Association, University of Mississippi, Jackson
A potential new
…
Read more
0
- in General Medicine
- — 21 Sep, 2007
BORIS: A. baumanni Highly Resistant Î²-Lactamase and Varying Susceptibility Patterns

Jennifer Lavrrar, Jane Hata, Jeanette Block
REFERENCE: Slide Session C2-1360, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007
JANE HATA, bioMÃ©rÃeux Inc, Durham
Reports from the BORIS study call for ongoing surveillance of multi-drug resistant Acinetobacter
…
Read more
0
- in Oncology
- — 31 Aug, 2007
KRAS Mutation: Powerful Molecular Predictor of Cetuximab Response in Patients With Metastatic Colorectal Cancer

Pierre Laurent-Puig

Bill Hait
REFERENCE: ABSTRACT: 5671, American Association for Cancer Research, April 14-18, 2007, Los Angeles
PIERRE LAURENT-PUIG, HÃ´pital EuropÃ©en Georges Pompidou, Paris
COMMENT: BILL HAIT, Johnson & Johnson, Raritan, NJ
The presence of the KRAS mutation in tumor
…
Read more
0
- in ASCO · Oncology
- — 5 Jun, 2007
ASCO Annual Meeting Daily News Podcasts – June 5th, 2007

Aimery de Gramont

Robert Mayer
MOSAIC Study Six Year Results: Adjuvant Oxaliplatin Adds Survival Advantage for Patients with Stage III Colorectal Cancer
REFERENCE: 4007, ASCO Annual Meeting Chicago June 1-5, 2007
AIMERY DE GRAMONT, St Antoine Hospital, Paris
COMMENT: ROBERT
…
Read more
0
- in ASCO · Oncology
- — 5 Jun, 2007
ASCO Annual Meeting Daily News Podcasts – June 4th, 2007

Josep Llovet

Robert Mayer
Sorafenib The â€˜New Standardâ€™ for Advanced Liver Cancer
REFERENCE: ABSTRACT 5 (Plenary Session), ASCO Annual Meeting Chicago June 1-5, 2007
JOSEP LLOVET, IDIBAPS Hospital Clinic, Barcelona, and Mount Sinai School of Medicine, New York
COMMENT: ROBERT
…
Read more